Early Christmas Sale - Ends Soon!
-35% Off Everything
NVS

Novartis AG (NVS)

Last Price$98.3(0.1%)
Market Cap$197.6B
LTM Revenue
$49.3B
YoY Growth
-5.8%
3Y CAGR
-2.0%
5Y CAGR
-0.1%
Stock quality & Intrinsic value
7/10
22.7% undervalued

Novartis AG Revenue

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
$28.2B
$32.5B
$36.7B
$38.9B
$42.6B
$45.1B
$51.6B
$59.4B
$57.6B
$58.8B
$53.6B
$50.4B
$49.4B
$50.1B
$53.2B
$48.7B
$49.9B
$52.9B
$51.8B
$46.7B
NVS
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for NVS and see if it's the right time to invest.
Dive in

Novartis AG (NVS) Revenue comparison analysis

Crunching data... Almost there!

NVS key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is Novartis AG's Revenue?

As of today, Novartis AG's last 12-month Revenue is $49.3B, based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is Novartis AG's Revenue growth rate?

Over the last year, Novartis AG's Revenue growth was (5.8%). The average annual Revenue growth rates for Novartis AG have been (0.4%) over the past three years, (0.1%) over the past five years.

3) Is Novartis AG's Revenue growth rate Good?

Over the last year, Novartis AG's Revenue growth was (5.8%), which is lower than industry growth of 0.1%. It indicates that Novartis AG's Revenue growth is Bad.

4) How does Novartis AG's Revenue growth rate compare to its peers?

Over the last year, Novartis AG's Revenue growth was (5.8%), which is lower than peer median growth of 13.8%. The list of peers includes JNJ, SNY, MRK, PFE, ABBV, AZN, BMY, LLY, AMGN, GILD etc.